You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥板塊跑贏大市升逾3%至8% 藥明生物、君實、石藥、翰森及中生跑贏
恆指今早(27日)高見17,342,現報17,220,回升176點或1%,總成交額417億元。 大和給予多隻醫藥股正面評級。醫藥股今天普遍跑贏,藍籌翰森(03692.HK)重越250天線(13.36元),最高見13.64元,現報13.6元,回升7.9%。獲大和看73.3元的藍籌藥明生物(02269.HK)重越20天線(46.05元),最高見46.75元,現報46.55元,回升4.6%;獲大和看102元的藥明康德(02359.HK)回升3.5%報95.5元,股價重越20天及10天線(95.25元)。 獲大和升價至58元的信達生物(01801.HK)重越10天線,最高見44.75元,現報44.1元,回升4.3%。君實生物(01877.HK)回升5.1%報18.82元,股價重越10天線(18.22元)。 獲大和分別看6.5元及3.2元的藍籌石藥(01093.HK)及中生製藥(01177.HK)高見6.5元及2.9元,現報6.46元及2.88元(撲50天線2.89元),分別續升7.5%及回升8.3%,前者升破百天線(6.13元)。 康希諾(06185.HK)、艾美疫苗(06660.HK)、三葉草生物-B(02197.HK)、金斯瑞生物(01548.HK)、騰盛博藥-B(02137.HK)、百濟神州(06160.HK)及四環醫藥(00460.HK)升逾3%至5%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account